What is Shattuck Labs, Inc.'s earnings per share (EPS)?

Shattuck Labs, Inc. (STTK) reported diluted earnings per share of $-0.70 for fiscal year 2025. This represents a 53.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Shattuck Labs, Inc. Financials

STTK

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows Shattuck Labs, Inc. (STTK) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI STTK FY2025 2026-05-07

Shattuck Labs is shrinking its research burn while using equity financing to preserve a liquid, debt-light balance sheet.

FY2025's lower cash burn came from a smaller research program, not better commercialization: R&D fell from $67.2M to $35.3M. Revenue also shrank, so operating cash flow improving to -$39.9M indicates a deliberate cost reset and narrower scientific footprint, not the kind of sales engine that would normally absorb fixed costs.

Cash stayed resilient at $54.2M despite roughly -$39.9M of operating cash burn because financing inflows replaced much of what operations used. Shares outstanding jumped to 63.3M, and liabilities fell to $8.6M, which points to runway support coming mainly from equity rather than borrowing.

Capital needs are overwhelmingly operating, not physical: capex was just $71K against free cash flow of -$40.0M, and free cash flow closely tracked operating cash flow. Like a lab bench rather than a factory floor, a 11.7x current ratio suggests near-term bills are manageable; the real cash demand is keeping research programs alive.

Financial Health Signals

Financial Health Score 61/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Shattuck Labs, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Dilution

R&D Intensity

Revenue Progress

Burn Trend

Balance Sheet

Altman Z-Score Safe

37.44

Shattuck Labs, Inc. scores 37.44, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($646.6M) relative to total liabilities ($8.6M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

3/7

Shattuck Labs, Inc. passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Low Quality

0.82x

For every $1 of reported earnings, Shattuck Labs, Inc. generates $0.82 in operating cash flow (-$39.9M OCF vs -$48.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$1.0M

YoY-82.5%

5Y CAGR-36.8%

Shattuck Labs, Inc. generated $1.0M in revenue in fiscal year 2025. This represents a decrease of 82.5% from the prior year.

EBITDA

-$47.8M

YoY+37.7%

Shattuck Labs, Inc.'s EBITDA was -$47.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 37.7% from the prior year.

Net Income

-$48.8M

YoY+35.3%

Shattuck Labs, Inc. reported -$48.8M in net income in fiscal year 2025. This represents an increase of 35.3% from the prior year.

EPS (Diluted)

$-0.70

YoY+53.0%

Shattuck Labs, Inc. earned $-0.70 per diluted share (EPS) in fiscal year 2025. This represents an increase of 53.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$40.0M

YoY+34.0%

Shattuck Labs, Inc. generated -$40.0M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 34.0% from the prior year.

Cash & Debt

$54.2M

YoY-5.6%

5Y CAGR-19.3%

Shattuck Labs, Inc. held $54.2M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

63M

YoY+32.6%

5Y CAGR+8.7%

Shattuck Labs, Inc. had 63M shares outstanding in fiscal year 2025. This represents an increase of 32.6% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

-5150.8%

YoY-3742.5pp

5Y CAGR-4779.0pp

Shattuck Labs, Inc.'s operating margin was -5150.8% in fiscal year 2025, reflecting core business profitability. This is down 3742.5 percentage points from the prior year.

Net Margin

-4880.9%

YoY-3562.8pp

5Y CAGR-4512.4pp

Shattuck Labs, Inc.'s net profit margin was -4880.9% in fiscal year 2025, showing the share of revenue converted to profit. This is down 3562.8 percentage points from the prior year.

Return on Equity

-59.2%

YoY+35.5pp

5Y CAGR-47.4pp

Shattuck Labs, Inc.'s ROE was -59.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 35.5 percentage points from the prior year.

Capital Allocation

R&D Spending

$35.3M

YoY-47.5%

5Y CAGR-1.2%

Shattuck Labs, Inc. invested $35.3M in research and development in fiscal year 2025. This represents a decrease of 47.5% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$71K

YoY+20.3%

5Y CAGR-37.2%

Shattuck Labs, Inc. invested $71K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 20.3% from the prior year.

STTK Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$1.0M-82.5%	$5.7M+245.3%	$1.7M+154.1%	$652K-97.8%	$30.0M+202.2%	$9.9M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$35.3M-47.5%	$67.2M-9.6%	$74.3M-10.4%	$82.9M+46.6%	$56.6M+50.9%	$37.5M
SG&A Expenses	$17.2M-9.7%	$19.1M-1.2%	$19.3M-8.4%	$21.1M+12.6%	$18.7M+99.6%	$9.4M
Operating Income	-$51.5M+36.1%	-$80.6M+12.4%	-$92.0M+11.0%	-$103.3M-128.3%	-$45.3M-22.6%	-$36.9M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$0	$0	$0	$0	$0	$0
Net Income	-$48.8M+35.3%	-$75.4M+13.6%	-$87.3M+14.4%	-$101.9M-126.7%	-$45.0M-22.9%	-$36.6M
EPS (Diluted)	$-0.70+53.0%	$-1.49+27.3%	$-2.05+14.9%	$-2.41-125.2%	$-1.07+54.7%	$-2.36

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$0	N/A	$1.0M	$0	$0	$0-100.0%	$3.0M+86.3%	$1.6M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$10.9M	N/A	$7.6M-12.2%	$8.7M-12.5%	$9.9M-35.6%	$15.4M-5.6%	$16.3M-15.2%	$19.2M
SG&A Expenses	$4.6M	N/A	$4.1M-5.8%	$4.4M-2.6%	$4.5M+5.3%	$4.2M-7.8%	$4.6M-13.7%	$5.3M
Operating Income	-$15.5M	N/A	-$10.7M+17.8%	-$13.0M+9.4%	-$14.4M+26.7%	-$19.6M-9.6%	-$17.9M+22.0%	-$23.0M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$14.8M	N/A	-$10.1M+19.3%	-$12.5M+9.1%	-$13.7M+26.6%	-$18.7M-12.0%	-$16.7M+22.6%	-$21.6M
EPS (Diluted)	$-0.13	N/A	$-0.14+41.7%	$-0.24+11.1%	$-0.27	N/A	$-0.33+21.4%	$-0.42

STTK Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$91.0M0.0%	$91.0M-42.9%	$159.6M-22.3%	$205.3M-31.2%	$298.6M-14.4%	$349.0M
Current Assets	$82.5M+4.1%	$79.2M-44.7%	$143.2M-22.4%	$184.6M-36.0%	$288.3M-16.6%	$345.6M
Cash & Equivalents	$54.2M-5.6%	$57.4M-54.3%	$125.6M+165.2%	$47.4M-48.7%	$92.3M-41.6%	$157.9M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$8.6M-24.4%	$11.4M-23.1%	$14.9M-49.1%	$29.2M+8.8%	$26.8M-31.5%	$39.1M
Current Liabilities	$7.1M-20.9%	$8.9M-22.1%	$11.5M-54.1%	$25.0M+1.5%	$24.6M+46.0%	$16.8M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$82.4M+3.5%	$79.6M-45.0%	$144.7M-17.9%	$176.2M-35.2%	$271.8M-12.3%	$309.9M
Retained Earnings	-$430.5M-12.8%	-$381.7M-24.6%	-$306.3M-39.9%	-$219.0M-87.1%	-$117.1M-62.4%	-$72.1M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$102.1M+12.2%	$91.0M-9.3%	$100.3M+55.9%	$64.4M-16.6%	$77.2M-15.2%	$91.0M-18.5%	$111.7M-13.1%	$128.6M
Current Assets	$93.8M+13.7%	$82.5M-9.1%	$90.7M+65.9%	$54.7M-17.7%	$66.4M-16.2%	$79.2M-19.8%	$98.7M-13.7%	$114.4M
Cash & Equivalents	$90.4M+66.8%	$54.2M+27.4%	$42.5M-15.7%	$50.5M-17.1%	$60.9M+6.1%	$57.4M+30.9%	$43.8M-27.8%	$60.7M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$86.0M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$6.3M-27.2%	$8.6M+21.8%	$7.1M-3.5%	$7.4M-23.3%	$9.6M-16.1%	$11.4M-24.6%	$15.1M-15.9%	$18.0M
Current Liabilities	$4.2M-39.7%	$7.1M+32.2%	$5.3M0.0%	$5.3M-27.1%	$7.3M-18.0%	$8.9M-28.1%	$12.4M-17.5%	$15.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$95.8M+16.3%	$82.4M-11.6%	$93.2M+63.5%	$57.0M-15.6%	$67.6M-15.1%	$79.6M-17.6%	$96.6M-12.7%	$110.6M
Retained Earnings	-$445.3M-3.4%	-$430.5M-3.0%	-$417.9M-2.5%	-$407.9M-3.2%	-$395.4M-3.6%	-$381.7M-5.1%	-$363.0M-4.8%	-$346.4M

STTK Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$39.9M+34.1%	-$60.5M+25.5%	-$81.2M+14.0%	-$94.5M-65.4%	-$57.1M-69.7%	-$33.7M
Capital Expenditures	$71K+20.3%	$59K-85.5%	$407K-96.5%	$11.6M+46.5%	$7.9M+990.2%	$727K
Free Cash Flow	-$40.0M+34.0%	-$60.6M+25.8%	-$81.6M+23.1%	-$106.1M-63.1%	-$65.0M-89.2%	-$34.4M
Investing Cash Flow	-$7.9M+7.3%	-$8.5M-107.7%	$110.9M+124.2%	$49.4M+573.4%	-$10.4M+92.9%	-$146.3M
Financing Cash Flow	$44.6M+5563.8%	$787K-98.4%	$48.6M+28330.4%	$171K-91.1%	$1.9M-99.4%	$330.9M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$13.4M-58.1%	-$8.5M+4.9%	-$8.9M+14.4%	-$10.4M+13.3%	-$12.0M+30.7%	-$17.4M-8.1%	-$16.1M-47.2%	-$10.9M
Capital Expenditures	N/A	$0-100.0%	$71K	N/A	N/A	$0-100.0%	$42K+147.1%	$17K
Free Cash Flow	N/A	-$8.5M+5.7%	-$9.0M	N/A	N/A	-$17.4M-7.8%	-$16.1M-47.3%	-$10.9M
Investing Cash Flow	$23.8M+19.2%	$20.0M+146.0%	-$43.5M	$0-100.0%	$15.6M-49.7%	$31.0M+3875.9%	-$821K+84.8%	-$5.4M
Financing Cash Flow	$25.8M+19156.0%	$134K-99.7%	$44.5M	$0+100.0%	-$57K+20.8%	-$72K-413.0%	$23K-97.7%	$1.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

STTK Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-5150.8%-3742.5pp	-1408.3%+4141.3pp	-5549.6%+10298.4pp	-15848.0%-15697.2pp	-150.8%+221.0pp	-371.8%
Net Margin	-4880.9%-3562.8pp	-1318.1%+3950.3pp	-5268.4%+10367.3pp	-15635.7%-15485.9pp	-149.8%+218.6pp	-368.5%
Return on Equity	-59.2%+35.5pp	-94.7%-34.4pp	-60.3%-2.5pp	-57.9%-41.3pp	-16.6%-4.7pp	-11.8%
Return on Assets	-53.6%+29.2pp	-82.8%-28.1pp	-54.7%-5.1pp	-49.6%-34.6pp	-15.1%-4.6pp	-10.5%
Current Ratio	11.70+2.8	8.88-3.6	12.51+5.1	7.39-4.3	11.72-8.8	20.53
Debt-to-Equity	0.10-0.0	0.14+0.0	0.10-0.1	0.17+0.1	0.10-0.0	0.13
FCF Margin	-3995.3%-2936.5pp	-1058.8%+3867.9pp	-4926.7%+11348.2pp	-16274.9%-16058.2pp	-216.7%+129.5pp	-346.1%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-1554.5%	N/A	-1071.6%	N/A	N/A	N/A	-597.9%+829.2pp	-1427.1%
Net Margin	-1476.7%	N/A	-1005.6%	N/A	N/A	N/A	-556.4%+783.1pp	-1339.5%
Return on Equity	-15.4%	N/A	-10.8%+11.1pp	-21.9%-1.6pp	-20.3%+3.2pp	-23.5%-6.2pp	-17.3%+2.2pp	-19.5%
Return on Assets	-14.5%	N/A	-10.0%+9.3pp	-19.4%-1.6pp	-17.8%+2.8pp	-20.5%-5.6pp	-14.9%+1.8pp	-16.8%
Current Ratio	22.06+10.4	11.70-5.3	17.00+6.8	10.25+1.2	9.08+0.2	8.88+0.9	7.96+0.3	7.62
Debt-to-Equity	0.07-0.0	0.10+0.0	0.08-0.1	0.13-0.0	0.140.0	0.14-0.0	0.160.0	0.16
FCF Margin	N/A	N/A	-900.0%	N/A	N/A	N/A	-537.5%+142.1pp	-679.6%

Similar Companies

Inflarx IFRX

$297.5M

Macrogenics Inc MGNX

$274.6M

Surrozen Inc SRZN

$253.0M

Anixa Biosciences Inc ANIX

$119.1M

Atara Biotherape ATRA

$77.0M

Frequently Asked Questions

What is Shattuck Labs, Inc.'s annual revenue?

Shattuck Labs, Inc. (STTK) reported $1.0M in total revenue for fiscal year 2025. This represents a -82.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Shattuck Labs, Inc.'s revenue growing?

Shattuck Labs, Inc. (STTK) revenue declined by 82.5% year-over-year, from $5.7M to $1.0M in fiscal year 2025.

Is Shattuck Labs, Inc. profitable?

No, Shattuck Labs, Inc. (STTK) reported a net income of -$48.8M in fiscal year 2025, with a net profit margin of -4880.9%.

What is Shattuck Labs, Inc.'s EBITDA?

Shattuck Labs, Inc. (STTK) had EBITDA of -$47.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Shattuck Labs, Inc.'s operating margin?

Shattuck Labs, Inc. (STTK) had an operating margin of -5150.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Shattuck Labs, Inc.'s net profit margin?

Shattuck Labs, Inc. (STTK) had a net profit margin of -4880.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Shattuck Labs, Inc.'s return on equity (ROE)?

Shattuck Labs, Inc. (STTK) has a return on equity of -59.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Shattuck Labs, Inc.'s free cash flow?

Shattuck Labs, Inc. (STTK) generated -$40.0M in free cash flow during fiscal year 2025. This represents a 34.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Shattuck Labs, Inc.'s operating cash flow?

Shattuck Labs, Inc. (STTK) generated -$39.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Shattuck Labs, Inc.'s total assets?

Shattuck Labs, Inc. (STTK) had $91.0M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Shattuck Labs, Inc.'s capital expenditures?

Shattuck Labs, Inc. (STTK) invested $71K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Shattuck Labs, Inc. spend on research and development?

Shattuck Labs, Inc. (STTK) invested $35.3M in research and development during fiscal year 2025.

How many shares does Shattuck Labs, Inc. have outstanding?

Shattuck Labs, Inc. (STTK) had 63M shares outstanding as of fiscal year 2025.

What is Shattuck Labs, Inc.'s current ratio?

Shattuck Labs, Inc. (STTK) had a current ratio of 11.70 as of fiscal year 2025, which is generally considered healthy.

What is Shattuck Labs, Inc.'s debt-to-equity ratio?

Shattuck Labs, Inc. (STTK) had a debt-to-equity ratio of 0.10 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Shattuck Labs, Inc.'s return on assets (ROA)?

Shattuck Labs, Inc. (STTK) had a return on assets of -53.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Shattuck Labs, Inc.'s cash runway?

Based on fiscal year 2025 data, Shattuck Labs, Inc. (STTK) had $54.2M in cash against an annual operating cash burn of $39.9M. This gives an estimated cash runway of approximately 16 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Shattuck Labs, Inc.'s Altman Z-Score?

Shattuck Labs, Inc. (STTK) has an Altman Z-Score of 37.44, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Shattuck Labs, Inc.'s Piotroski F-Score?

Shattuck Labs, Inc. (STTK) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Shattuck Labs, Inc.'s earnings high quality?

Shattuck Labs, Inc. (STTK) has an earnings quality ratio of 0.82x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Shattuck Labs, Inc.?

Shattuck Labs, Inc. (STTK) scores 61 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.